You are here: Welcome » COVID-19 » COVID-19 Treatments and Philosophies » Sotrovimab (Xevudy) Antibody

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
covid-19:treatments:sotrovimab [2022/01/14 22:25]
brian 		covid-19:treatments:sotrovimab [2023/03/18 23:36] (current)
liam
Line 8: Line 8:
  
 Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the investigational monoclonal antibody therapeutic was granted on May 26, 2021 Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the investigational monoclonal antibody therapeutic was granted on May 26, 2021
 +
 +==Clinical Trials==
 +COMET-ICE Phase 3 RCT: 1,057 adult participants were randomized to sotrovimab or placebo. The trial demonstrated a 79% reduction in hospitalization (6/528 vs placebo 30/529) for those that received the treatment.(([[https://www.medrxiv.org/content/10.1101/2021.11.03.21265533v1|Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial]]))
 +
  
 ==Sales== ==Sales==
-11 January 2021 U.S.A. purchased 600,000 doses((https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-announce-united-states-government-0))+11 January 2022 U.S.A. purchased 600,000 doses((https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-announce-united-states-government-0)) \\ 
 +17 November 2021 U.S.A. purchases $1 billion worth of the mab((https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-announce-united-states-government)) 
 + 
 +===== External links ===== 
 + 
 +  * [[https://en.wikipedia.org/wiki/Sotrovimab|Wikipedia]]
  
Back to top